

# 226 - References

## References

230 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Millgate E, et al. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. *Psychol Med* 2022; 52:1-13.
2. Yoshimura B, et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. *Psychiatry Res* 2017; 250:65-70.
3. Shah P, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. *Psychiatry Res* 2018; 268:114-122.
4. Molins C, et al. Response to antipsychotic drugs in treatment-resistant schizophrenia: conclusions based on systematic review. *Schizophr Res* 2016; 178:64-67.
5. Samara MT, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. *JAMA Psychiatry* 2016; 73:199-210.
6. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry* 2017; 16:77-89.
7. Luykx JJ, et al. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. *Br J Psychiatry* 2020; 217:498-505.
8. Anand R, et al. Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia. *Int J Neuropsychopharmacol* 2023; 26:523-528.
9. Bugarski-Kirola D, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. *Lancet Psychiatry* 2016; 3:1115-1128.
10. Garay RP, et al. Potential serotonergic agents for the treatment of schizophrenia. *Expert Opin Investig Drugs* 2016; 25:159-170.
11. de Bartolomeis A, et al. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. *Expert Opin Pharmacother* 2022; 23:2035-2052.
12. Akhondzadeh S, et al. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2005; 29:253-259.

13. Brunstein MG, et al. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. *J Clin Psychiatry* 2005; 66:213–219.
14. Buie LW, et al. Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia. *Ann Pharmacother* 2006; 40:2200–2204.
15. Dickerson FB, et al. A double-blind trial of adjunctive allopurinol for schizophrenia. *Schizophr Res* 2009; 109:66–69.
16. Kontaxakis VP, et al. Switching to amisulpride monotherapy for treatment-resistant schizophrenia. *Eur Psychiatry* 2006; 21:214–217.
17. Lochmann van Bennekom MWH, et al. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders: a systematic review and meta-analysis of individual patient data. *Schizophr Res* 2024; 272:1–11.
18. Kane JM, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. *J Clin Psychiatry* 2007; 68:213–223.
19. Hsu WY, et al. Aripiprazole in treatment-refractory schizophrenia. *J Psychiatr Pract* 2009; 15:221–226. Treatment Examples Comments Strength of evidence Physical treatments ECT, rTMS, tDCS, DBS Best evidence for ECT as adjunct to clozapine. Others still largely experimental. Modest ++ Adjunctive antidepressants Mirtazapine, vortioxetine, SSRIs Limited data available suggest small benefits in negative and cognitive symptoms. Weak + Adjunctive anticonvulsants Lamotrigine, topiramate, sodium valproate, carbamazepine Data difficult to interpret Weak + Psychological therapies CBT Conflicting findings, effects small. Very weak ± CBT, cognitive behavioural therapy; DBS, deep brain stimulation; NSAIDs, non-steroidal anti-inflammatory drugs; rTMS, repetitive transcranial magnetic stimulation; tDCS, transcranial direct current stimulation. Table 1.54 (Continued)

Schizophrenia and related psychoses CHAPTER 1

20. Crossman AM, et al. Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients. *J Clin Psychiatry* 2006; 67:1158–1159.
21. Kishi T, et al. Asenapine add-on treatment for schizophrenia adults who received antipsychotics: a 52-week, open-label study. *Psychiatry Clin Neurosci* 2023; 77:365–366.
22. Tachibana M, et al. Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: a retrospective analysis. *Asian J Psychiatr* 2016; 24:28–32.
23. Tang S, et al. Efficacy of add-on blonanserin in treatment-resistant schizophrenia therapy: a retrospective cohort study. *Asian J Psychiatr* 2024; 91:103867.
24. Aibel T. Cariprazine: patients with treatment-resistant schizophrenia. *Neuropsychiatr Dis Treat* 2021; 17:2327–2332.
25. Montgomery A, et al. Cariprazine: an alternative treatment for clozapine-resistant schizophrenia? *Clin Psychopharmacol Neurosci* 2023; 21:202–206.
26. Boydston C, et al. Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects. *Int Clin Psychopharmacol* 2023; 38:361–366.
27. Valmaggia LR, et al. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication: randomised controlled trial. *Br J Psychiatry* 2005; 186:324–330.
28. Polese D, et al. Treatment-resistant to antipsychotics: a resistance to everything? Psychotherapy in treatment-resistant schizophrenia and nonaffective psychosis: a 25-year systematic review and exploratory meta-analysis. *Front Psychiatry* 2019; 10:210.
29. Corripio I, et al. Deep brain stimulation in treatment resistant schizophrenia: a pilot randomized cross-over clinical trial. *EBioMedicine* 2020; 51:102568.
30. Tsai GE, et al. D-alanine added to antipsychotics for the treatment of schizophrenia. *Biol Psychiatry* 2006; 59:230–234.
31. Heresco-Levy U, et al. D-serine efficacy as add-on

pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. *Biol Psychiatry* 2005; 57:577–585. 32. Ermilov M, et al. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. *Schizophr Res* 2013; 150:604–605. 33. Zheng W, et al. Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. *PLoS One* 2016; 11:e0156510. 34. Grover S, et al. Effectiveness of electroconvulsive therapy in patients with treatment resistant schizophrenia: a retrospective study. *Psychiatry Res* 2017; 249:349–353. 35. Chanpattana W, et al. Electroconvulsive therapy in treatment-resistant schizophrenia: prediction of response and the nature of symptomatic improvement. *J ECT* 2010; 26:289–298. 36. Ravanic DB, et al. Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. *Psychiatr Danub* 2009; 21:179–186. 37. Melzer-Ribeiro DL, et al. Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia. *Schizophr Res* 2024; 268:252–260. 38. Kulkarni J, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. *Mol Psychiatry* 2015; 20:695–702. 39. Li Z, et al. Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Acta Psychiatr Scand* 2023; 147:360–372. 40. Meskanen K, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. *J Clin Psychopharmacol* 2013; 33:472–478. 41. Chen X, et al. Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. *Psychiatry Res* 2015; 228:121–127. 42. Meltzer H, et al. W162 lurasidone is an effective treatment for treatment resistant schizophrenia. *Neuropsychopharmacology* 2015; 40 Suppl 1:S546. 43. Meltzer HY, et al. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. *J Clin Psychopharmacol* 2020; 40:240–249. 44. Lowe P, et al. When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity. *Ther Adv Psychopharmacol* 2018; 8:63–70. 45. Lieberman JA, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. *Neuropsychopharmacology* 2009; 34:1322–1329. 46. de Lucena D, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. *J Clin Psychiatry* 2009; 70:1416–1423. 47. Rezaei F, et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol* 2013; 33:336–342. 48. Levkovitz Y, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. *J Clin Psychiatry* 2010; 71:138–149. 49. Miyaoka T, et al. Minocycline as adjunctive therapy for schizophrenia: an open-label study. *Clin Neuropharmacol* 2008; 31:287–292. 50. Kelly DL, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. *J Clin Psychopharmacol* 2015; 35:374–381. 51. Chaudhry IB, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. *J Psychopharmacol* 2012; 26:1185–1193. 52. Joffe G, et al. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. *Schizophr Res* 2009; 108:245–251.

232 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 53. Berk M, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. *Hum Psychopharmacol* 2009; 24:233–238. 54. Delle CR, et al. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. *Exp Clin Psychopharmacol* 2007; 15:563–568. 55. Sepehrmanesh Z, et al. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: a double-blind, randomized clinical trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2017; 82:289–296. 56. Bulut M, et al. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. *World J Biol Psychiatry* 2009; 10:626–628. 57. Neill E, et al. N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double-blind, randomized, placebo-controlled trial targeting negative symptoms. *Schizophr Bull* 2022; 48:1263–1272. 58. Breier A, et al. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. *Biol Psychiatry* 1999; 45:403–411. 59. Conley RR, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. *Am J Psychiatry* 1998; 155:914–920. 60. Sanders RD, et al. An open trial of olanzapine in patients with treatment-refractory psychoses. *J Clin Psychopharmacol* 1999; 19:62–66. 61. Taylor D, et al. Olanzapine in practice: a prospective naturalistic study. *Psychiatr Bull* 1999; 23:178–180. 62. Bitter I, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; 28:173–180. 63. Tollefson GD, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. *Biol Psychiatry* 2001; 49:52–63. 64. Gannon L, et al. High-dose olanzapine in treatment-resistant schizophrenia: a systematic review. *Ther Adv Psychopharmacol* 2023; 13:20451253231168788. 65. Bronson BD, et al. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. *J Clin Psychopharmacol* 2000; 20:382–384. 66. Kelly DL, et al. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. *Ann Clin Psychiatry* 2003; 15:181–186. 67. Meltzer HY, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. *J Clin Psychiatry* 2008; 69:274–285. 68. Heresco-Levy U, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. *Biol Psychiatry* 2004; 55:165–171. 69. Dursun SM, et al. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. *J Psychopharmacol* 2001; 15:297–301. 70. Zheng W, et al. Adjunctive ondansetron for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *J Psychiatr Res* 2019; 113:27–33. 71. Martínez-Andrés JA, et al. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. *Int Clin Psychopharmacol* 2020; 35:163–169. 72. Nasrallah HA, et al. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. *Schizophr Res* 2019; 208:217–220. 73. Salimi S, et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32:726–732. 74. Reznik I, et al. Long-term efficacy and safety of quetiapine in treatment-refractory schizophrenia: a case report. *Int J Psychiatry Clin Pract* 2000; 4:77–80. 75. De Nayer A, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. *Int J Psychiatry Clin Pract* 2003; 7:59–66. 76. Larmo I, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. *Hum Psychopharmacol* 2005; 20:573–581. 77. Boggs DL, et al. Quetiapine at high doses for the treatment of refractory

schizophrenia. *Schizophr Res* 2008; 101:347–348. 78. Lindenmayer JP, et al. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. *J Clin Psychopharmacol* 2011; 31:160–168. 79. Usall J, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. *Schizophr Bull* 2016; 42:309–317. 80. Usall J, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. *J Clin Psychiatry* 2011; 72:1552–1557. 81. Weiser M, et al. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. *J Clin Psychiatry* 2017; 78:e758–e765. 82. Kulkarni J, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. *JAMA Psychiatry* 2016; 73:947–954. 83. Farokhnia M, et al. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. *Psychopharmacology (Berl)* 2014; 231:533–542. 84. Breier AF, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. *Am J Psychiatry* 1999; 156:294–298. 85. Bondolfi G, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. *Am J Psychiatry* 1998; 155:499–504.

Schizophrenia and related psychoses CHAPTER 1 86. Conley RR, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. *Clin Neuropharmacol* 2005; 28:163–168. 87. Lerner V, et al. Combination of ‘atypical’ antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; 28:89–98. 88. Meltzer HY, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. *Schizophr Res* 2014; 154:14–22. 89. Lane HY, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. *Arch Gen Psychiatry* 2005; 62:1196–1204. 90. Tsai G, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. *Biol Psychiatry* 2004; 55:452–456. 91. Marchi M, et al. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *Expert Opin Drug Metab Toxicol* 2021; 17:483–493. 92. Kane JM, et al. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. *J Clin Psychiatry* 2011; 72:194–204. 93. Nielsen J, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2012; 32:173–178. 94. Tiihonen J, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. *J Clin Psychiatry* 2005; 66:1012–1015. 95. Lorentzen R, et al. The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. *Schizophrenia (Heidelb)* 2022; 8:35. 96. Guttesen LL, et al. Repetitive transcranial magnetic stimulation and transcranial direct current stimulation for auditory hallucinations in schizophrenia: systematic review and meta-analysis. *J Psychiatr Res* 2021; 143:163–175. 97. Khosravi M. Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia: a case report. *J Med Case Rep* 2020; 14:137. 98. Basan A, et al. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. *Schizophr Res* 2004; 70:33–37. 99. Miyaoka T, et al. Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a

randomized, multicenter, double-blind, placebo- controlled trial. Evid Based Complement Alternat Med 2015; 2015:201592. 100. Horiguchi J, et al. A multicenter, double-blind, randomized, controlled study of patients with treatment-resistant schizophrenia treated with yokukansan for 12 weeks. PCN Rep 2023; 2:e155. 101. Sacchetti E, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009; 110:80-89. 102. Loebel AD, et al. Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. J Clin Psychiatry 2007; 68:1333-1338. 103. Kane JM, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006; 21:21-28. 104. Goff DC, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol 2013; 33:485-490. 105. Lin CC, et al. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. J Clin Psychopharmacol 2013; 33:211-214.

---

Revision #1

Created 2026-01-04 20:13:18 UTC by Omar Ayman

Updated 2026-01-04 20:13:18 UTC by Omar Ayman